Altimmune/ALT

$12.09

0.74%
-
1D1W1MYTD1YMAX

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Ticker

ALT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Vipin Garg

Employees

52

Headquarters

Gaithersburg, United States

Altimmune Metrics

BasicAdvanced
$649.58M
Market cap
-
P/E ratio
-$1.57
EPS
0.07
Beta
-
Dividend rate

What the Analysts think about Altimmune

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
79.9% upside
High $35.00
Low $13.00
$12.09
Current price
$21.75
Average price target

Altimmune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-6,866.66% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$300K
∞%
Net income
$-20.6M
28.75%
Profit margin
-6,866.66%
-∞%

Altimmune Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.14%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.43
-$0.40
-$0.32
-$0.39
-
Expected
-$0.50
-$0.48
-$0.46
-$0.42
-$0.43
Surprise
-14.25%
-16.58%
-31.12%
-8.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Altimmune stock

Buy or sell Altimmune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing